CA2486362A1 - Novel recombinant anticoagulant proteins - Google Patents

Novel recombinant anticoagulant proteins Download PDF

Info

Publication number
CA2486362A1
CA2486362A1 CA002486362A CA2486362A CA2486362A1 CA 2486362 A1 CA2486362 A1 CA 2486362A1 CA 002486362 A CA002486362 A CA 002486362A CA 2486362 A CA2486362 A CA 2486362A CA 2486362 A1 CA2486362 A1 CA 2486362A1
Authority
CA
Canada
Prior art keywords
anv
seq
recombinant
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002486362A
Other languages
English (en)
French (fr)
Inventor
Tze Chein Wun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2486362A1 publication Critical patent/CA2486362A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721Lipocortins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002486362A 2002-06-06 2003-06-04 Novel recombinant anticoagulant proteins Abandoned CA2486362A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38693202P 2002-06-06 2002-06-06
US60/386,932 2002-06-06
PCT/US2003/017442 WO2003103577A2 (en) 2002-06-06 2003-06-04 Novel recombinant anticoagulant proteins

Publications (1)

Publication Number Publication Date
CA2486362A1 true CA2486362A1 (en) 2003-12-18

Family

ID=29736237

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002486362A Abandoned CA2486362A1 (en) 2002-06-06 2003-06-04 Novel recombinant anticoagulant proteins

Country Status (8)

Country Link
US (2) US7378393B2 (enExample)
EP (1) EP1509541B1 (enExample)
JP (1) JP4444821B2 (enExample)
CN (1) CN1659180B (enExample)
AT (1) ATE534658T1 (enExample)
AU (1) AU2003237351B2 (enExample)
CA (1) CA2486362A1 (enExample)
WO (1) WO2003103577A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7671013B2 (en) * 2003-04-03 2010-03-02 Canadian Blood Services, Inc. Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses
CA2559167A1 (en) * 2004-03-11 2005-09-22 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
US7511016B2 (en) * 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
EP2234631B1 (en) 2007-12-18 2012-09-12 Athera Biotechnologies AB Compounds and methods for the treatment of vascular disease
TR201909412T4 (tr) * 2008-02-22 2019-07-22 Annexin Pharmaceuticals Ab Restenozun önlenmesi veya tedavisi için bileşikler ve yöntemler.
JP5590621B2 (ja) 2008-10-17 2014-09-17 ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド 炎症性障害の処置を処置するためのアネキシンおよびその使用
JP6200806B2 (ja) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
US10040840B2 (en) 2015-10-02 2018-08-07 Silver Creek Pharmaceuticals, Inc. Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
CN113956339B (zh) * 2021-10-28 2023-02-24 中国药科大学 宽体金线蛭抗凝血因子XIa多肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007676A1 (fr) 1987-03-27 1988-10-06 Terumo Kabushiki Kaisha Capteur enzymatique
WO1998029453A1 (en) 1996-12-27 1998-07-09 Mochida Pharmaceutical Co., Ltd. Cell membrane-directed drugs

Also Published As

Publication number Publication date
US7378393B2 (en) 2008-05-27
EP1509541A2 (en) 2005-03-02
JP4444821B2 (ja) 2010-03-31
AU2003237351A2 (en) 2003-12-22
WO2003103577A2 (en) 2003-12-18
CN1659180B (zh) 2010-06-02
CN1659180A (zh) 2005-08-24
AU2003237351A1 (en) 2003-12-22
US20050164926A1 (en) 2005-07-28
AU2003237351B2 (en) 2009-12-03
US20090029444A1 (en) 2009-01-29
EP1509541A4 (en) 2006-06-07
JP2005528124A (ja) 2005-09-22
ATE534658T1 (de) 2011-12-15
EP1509541B1 (en) 2011-11-23
WO2003103577A3 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
US20090029444A1 (en) Novel recombinant anticoagulant proteins
US5874407A (en) Factor VIIA inhibitors
JP3811186B2 (ja) 線虫から抽出されるセリンプロテアーゼ阻害剤および抗凝固性タンパク質
US5409895A (en) Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof
Wesselschmidt et al. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa
JP3051995B2 (ja) 酸化抵抗性トロンボモジュリン類縁体
US5780265A (en) Kunitz type plasma kallikrein inhibitors
KR100356956B1 (ko) 사람비쿠닌
KR100278036B1 (ko) 사람 쿠니즈형 프로테아제 저해제 변이체
JP3345420B2 (ja) 新規のヒトクニツ型プロテアーゼインヒビター及びその変異体
US6113896A (en) Pharmaceutical compositions containing ecotin and homologs thereof
JPH09509838A (ja) クニッツドメイン拮抗剤蛋白質
JP2012525836A (ja) セリンプロテアーゼインヒビターの改変方法
EP0866870B1 (en) TISSUE FACTOR - KUNITZ DOMAIN FUSION PROTEINS AS FACTOR VIIa INHIBITORS
JP2010533684A (ja) 血液凝固異常の治療又は予防のための変異アンチトロンビンの使用
Chen et al. Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants
Hagemeyer et al. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide
JP2009528831A (ja) キメラKunitzドメインおよびその使用
JP4339962B2 (ja) ヒトアンチトロンビン変異体
US6841534B2 (en) Protein Z-dependent protease inhibitor
JP2000503528A (ja) 第VIIa因子の新規阻害剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20121022